title: Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?
authors.forename: Maciej Bogdan
authors.initials: MB
authors.lastname: Maniecki
authors.forename: Henrik
authors.initials: H
authors.lastname: Hasle
authors.forename: Knud
authors.initials: K
authors.lastname: Bendix
authors.forename: Holger Jon
authors.initials: HJ
authors.lastname: Møller
mesh_terms: D000208:Acute Disease; D000617:Aminoglycosides / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D015703:Antigens, CD / Q000378:metabolism*; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000378:metabolism; D000079982:Gemtuzumab; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007951:Leukemia, Myeloid / Q000188:drug therapy; D063268:Sialic Acid Binding Ig-like Lectin 3
chemical_list: D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000970:Antineoplastic Agents; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab